Abstract
Purpose
Poria cocos and Morus alba L., recognized as traditional Chinese medicines (TCMs), have gained attention for their diverse pharmacological effects. An herbal extract mixture (named as NB-02) combining these two botanicals has been developed for the prevention and treatment of Alzheimer's disease (AD). To ensure the efficacy and safety of NB-02, we aimed to evaluate the pharmacokinetic profile and herb-drug interaction potential of the major bioactive compounds, poricoic acid A (PAA) and quinic acid (QA), in NB-02.
Methods
The plasma concentration profiles of PAA and QA were assessed in rats following oral administration of the extract mixture while evaluating the dose and sex-related pharmacokinetic characteristics. Also, potential herb-drug interactions of the extract mixture were evaluated through cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) inhibition assays. P-glycoprotein (P-gp) substrate and inhibitor prediction was conducted in silico.
Results
A pharmacokinetic study revealed a dose-dependent increase in plasma levels of PAA and QA. PAA exhibited no sex-specificity, whereas QA demonstrated elevated plasma levels in female rats. Furthermore, NB-02 showed no significant inhibitory effects on the activities of both CYP and UGT enzymes. Also, PAA and QA were predicted to be P-gp non-inhibitors.
Conclusion
The investigation of the pharmacokinetic properties and herb-drug interactions of the major bioactive compounds, PAA and QA, would provide valuable insights into the pharmacological effects and potential clinical application of NB-02.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
References
Archer DF (2013) The importance of pharmacokinetic studies in drug development. Contraception 87:701–702. https://doi.org/10.1016/j.contraception.2013.04.004
Beierle I, Meibohm B, Derendorf H (1999) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529–547
Benali T, Bakrim S, Ghchime R et al (2022) Pharmacological insights into the multifaceted biological properties of quinic acid. Biotechnol Genet Eng Rev. https://doi.org/10.1080/02648725.2022.2122303
Chang BY, Koo BS, Kim SY (2021) Pharmacological activities for Morus alba L., focusing on the immunostimulatory property from the fruit aqueous extract. Foods. https://doi.org/10.3390/foods10081966
Chen Y, Liu L, Monshouwer M, Fretland AJ (2011) Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions. Drug Metab Dispos 39:2085–2092. https://doi.org/10.1124/dmd.111.040634
Chen DQ, Feng YL, Chen L, Liu JR, Wang M, Vaziri ND, Zhao YY (2019) Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFkappaB/Nrf2 axis. Free Radic Biol Med 134:484–497. https://doi.org/10.1016/j.freeradbiomed.2019.01.046
Chen YY, Wang MC, Wang YN, Hu HH, Liu QQ, Liu HJ, Zhao YY (2020) Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy. Biomark Res 8:42. https://doi.org/10.1186/s40364-020-00218-z
Fletcher CV, Acosta EP, Strykowski JM (1994) Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 15:619–629. https://doi.org/10.1016/s1054-139x(94)90628-9
Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T (2015) The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med 13:74. https://doi.org/10.1186/s12916-015-0322-7
Hammes JA, Pfuetzenreiter F, Silveira F, Koenig A, Westphal GA (2008) Potential drug interactions prevalence in intensive care units. Rev Bras Ter Intensiva 20:349–354
He SM, Li CG, Liu JP, Chan E, Duan W, Zhou SF (2010) Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr Med Chem 17:4072–4113. https://doi.org/10.2174/092986710793205336
Heredi-Szabo K, Palm JE, Andersson TB, Pal A, Mehn D, Fekete Z, Beery E, Jakab KT, Jani M, Krajcsi P (2013) A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing. Eur J Pharm Sci 49:773–781. https://doi.org/10.1016/j.ejps.2013.04.032
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170. https://doi.org/10.1093/hmg/ddh019
Joo J, Lee B, Lee T, Liu KH (2014) Screening of six UGT enzyme activities in human liver microsomes using liquid chromatography/triple quadrupole mass spectrometry. Rapid Commun Mass Spectrom 28:2405–2414. https://doi.org/10.1002/rcm.7030
Kaur D, Behl T, Sehgal A, Singh S, Sharma N, Bungau S (2021) Multifaceted Alzheimer’s disease: building a roadmap for advancement of novel therapies. Neurochem Res 46:2832–2851. https://doi.org/10.1007/s11064-021-03415-w
Larson B, Kelts JL, Banks P, Cali JJ (2011) Automation and miniaturization of the bioluminescent UGT-Glo assay for screening of UDP-glucuronosyltransferase inhibition by various compounds. J Lab Autom 16:38–46. https://doi.org/10.1016/j.jala.2010.05.005
Lee SR, Lee S, Moon E, Park HJ, Park HB, Kim KH (2017) Bioactivity-guided isolation of anti-inflammatory triterpenoids from the sclerotia of Poria cocos using LPS-stimulated Raw264.7 cells. Bioorg Chem 70:94–99. https://doi.org/10.1016/j.bioorg.2016.11.012
Lee YF, Lariviere L, Russ AN, Choi SZ, Bacskai BJ, Kastanenka KV (2021) Novel botanical therapeutic NB-02 effectively treats Alzheimer’s neuropathophysiology in an APP/PS1 mouse model. eNeuro. https://doi.org/10.1523/ENEURO.0389-20.2021
Li X, Hu J, Wang B, Sheng L, Liu Z, Yang S, Li Y (2014) Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp. Toxicol Appl Pharmacol 275:163–175. https://doi.org/10.1016/j.taap.2013.12.015
Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–449
Liu C, Cao YF, Fang ZZ, Zhang YY, Hu CM, Sun XY, Huang T, Zeng J, Fan XR, Mo H (2012) Strong inhibition of deoxyschizandrin and schisantherin A toward UDP-glucuronosyltransferase (UGT) 1A3 indicating UGT inhibition-based herb-drug interaction. Fitoterapia 83:1415–1419. https://doi.org/10.1016/j.fitote.2012.08.004
Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329–342. https://doi.org/10.2165/00003088-200241050-00002
Mortele O, Jorissen J, Spacova I, Lebeer S, Van Nuijs ALN, Hermans N (2021) Demonstrating the involvement of an active efflux mechanism in the intestinal absorption of chlorogenic acid and quinic acid using a Caco-2 bidirectional permeability assay. Food Funct 12:417–425. https://doi.org/10.1039/d0fo02629h
Pagnier GJ, Kastanenka KV, Sohn M, Choi S, Choi SH, Soh H, Bacskai BJ (2018) Novel botanical drug DA-9803 prevents deficits in Alzheimer’s mouse models. Alzheimers Res Ther 10:11. https://doi.org/10.1186/s13195-018-0338-2
Seo KA, Kim HJ, Jeong ES, Abdalla N, Choi CS, Kim DH, Shin JG (2014) In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 42:1803–1810. https://doi.org/10.1124/dmd.114.058818
Shal B, Ding W, Ali H, Kim YS, Khan S (2018) Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease. Front Pharmacol 9:548. https://doi.org/10.3389/fphar.2018.00548
Sun Y (2014) Biological activities and potential health benefits of polysaccharides from Poria cocos and their derivatives. Int J Biol Macromol 68:131–134. https://doi.org/10.1016/j.ijbiomac.2014.04.010
Sun J, Zhang L, Song J, Tian S, Huang C, Feng Z, Lv Y, Du G (2013) Pharmacokinetic study of salvianolic acid A in beagle dog after oral administration by a liquid chromatography-mass spectrometry method: a study on bioavailability and dose proportionality. J Ethnopharmacol 148:617–623. https://doi.org/10.1016/j.jep.2013.05.013
Tang C, Bao T, Zhang Q, Qi H, Huang Y, Zhang B, Zhao L, Tong X (2023) Clinical potential and mechanistic insights of mulberry (Morus alba L.) leaves in managing type 2 diabetes mellitus: focusing on gut microbiota, inflammation, and metabolism. J Ethnopharmacol 306:116143. https://doi.org/10.1016/j.jep.2023.116143
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738. https://doi.org/10.1073/pnas.84.21.7735
Ukiya M, Akihisa T, Tokuda H, Hirano M, Oshikubo M, Nobukuni Y, Kimura Y, Tai T, Kondo S, Nishino H (2002) Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos. J Nat Prod 65:462–465. https://doi.org/10.1021/np0103721
Wang J, Li G, Rui T, Kang A, Li G, Fu T, Li J, Di L, Cai B (2017) Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality. RSC Adv 7:9057–9063. https://doi.org/10.1039/c6ra28237g
Wang PH, Tu YS, Tseng YJ (2019) PgpRules: a decision tree based prediction server for P-glycoprotein substrates and inhibitors. Bioinformatics 35:4535. https://doi.org/10.1093/bioinformatics/btz546
Ye M, Tang L, Luo M, Zhou J, Guo B, Liu Y, Chen B (2014) Size- and time-dependent alteration in metabolic activities of human hepatic cytochrome P450 isozymes by gold nanoparticles via microsomal coincubations. Nanoscale Res Lett 9:642. https://doi.org/10.1186/1556-276x-9-642
Yin L-H, Xu L-N, Han X et al (2010) Determination of poricoic acid A in rat plasma after oral and intravenous administration by LC–MS–MS and its application to a pharmacokinetic study. Chroma 72:465–472. https://doi.org/10.1365/s10337-010-1674-y
Zhao YY, Li HT, Feng YL, Bai X, Lin RC (2013) Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats. J Ethnopharmacol 148:403–410. https://doi.org/10.1016/j.jep.2013.04.018
Zhou W, Tam KY, Meng M, Shan J, Wang S, Ju W, Cai B, Di L (2015) Pharmacokinetics screening for multi-components absorbed in the rat plasma after oral administration of traditional Chinese medicine Flos Lonicerae Japonicae-Fructus Forsythiae herb couple by sequential negative and positive ionization ultra-high-performance liquid chromatography/tandem triple quadrupole mass spectrometric detection. J Chromatogr A 1376:84–97. https://doi.org/10.1016/j.chroma.2014.12.018
Acknowledgements
This work was supported by National Research Foundation of Korea (NRF) Grants funded by the Ministry of Education (2021R1A2C1010428) and National Research Foundation of Korea (NRF) Grant funded by the Korea government (MSIT) (RS-2023-00217123).
Funding
This work was supported by Dong-A ST Co., Ltd.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
All authors (S.Y. Yun, J.I. Seo, S.Z. Choi, J.Y. Ryu, A.Y. Park, and H.H. Yoo) declare that they have no conflict of interest.
Research involving human and animal rights
All animal procedures were approved by the Institutional Animal Care and Use Committee of Hanyang University (2017-0064A).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yun, S.Y., Seo, J.I., Choi, S.Z. et al. Exploring pharmacokinetics and herb-drug interactions of an herbal extract mixture derived from Poria cocos and Morus alba L.. J. Pharm. Investig. 54, 375–387 (2024). https://doi.org/10.1007/s40005-023-00658-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-023-00658-3